Patient-Derived Xenograft Models
Creative Animodel is a contract research organization providing pharmacological services based on our disease models. With years of experience, our professional scientists have established various patient-derived xenograft models to help our clients to study diseases and facilitate drug development. We are confident to offer optimal experiment plans and execution.
What Are Patient-Derived Xenograft Models?
Patient-derived xenograft (PDX), also known as patient-derived tumor xenograft (PDTX), is created by transferring primary tumors from the patient into an immunodeficient mouse or rat. Tumors can be engrafted heterotopically or orthotopically. Heterotopic PDX models involve implanting tumors into the subcutaneous flank of a mouse, which allows for easier cell transfer and precise monitoring of tumor growth and location. While orthotopic models involve direct implantation to mouse organ of choice, which is more technically challenging and time consuming but is considered to be more accurately mimicing human tumors. As shown in Figure 1, fresh tumor tissues are obtained and then section them into pieces, followed by subcutaneous or orthotopic implantation into an immunodeficient mouse or rat. During the engraftment phase, tumors are allowed to establish and grow and then are harvested upon reaching a size of 1500 mm3. Similar protocols are employed for subsequent expansion cohort and treatment cohort.
Figure 1. Overview of the methodology to establish PDX models and their uses in cancer research. (Lai Y, 2017)
Why Choose Patient-Derived Xenograft Models?
PDXs have some biologically stable characteristic, such as global gene expression patterns, mutational status, metastatic potential, drug responsiveness and tumor architecture, which may provide improvements over standard cell-line xenograft models. What’s more, establishing tumors models from patient-derived tumor tissue is generally agreed to conserve original tumor characteristic in terms of clinical biomolecular signature, tumor architecture, and tumor vasculature. With these characteristics, PDX can provide predictive viewpoints about evaluating the efficacy of novel cancer therapies.
Highly immune deficient mice that can be successfully transplanted with a wide variety of tumors are used in our company. The mice have almost no rejection of human tissues and high efficiency in establishing PDX models. Moreover, subcutaneous, orthotopic, and disseminated models are available depending on clients’ needs.
• Cancer types.
We provide numerous PDX models covering most cancer types, including both solid tumor and blood cancer, such as brain cancer, bladder cancer, breast cancer, ovarian cancer, pancreatic cancer, lung cancer and acute myeloid leukemia.
We offer detailed annotation about our PDX models, including patient information, diagnosis, genomic profiling and so on.
With PDX models, we can conduct studies including preclinical drug screening, in vivo and ex vivo efficacy testing, preclinical combination therapeutics screening as well as identification and analysis of biomarkers.
We offer customized study designs to accommodate effectiveness of novel drugs or existing therapeutic compounds depending on clients’ needs.
Creative Animodel provides a wide variety of patient-derived xenografts models to further facilitate drug development process in a fast and cost-efficient manner. Our high-quality services and reliable results make it possible to meet various demands of our clients. If you have any questions, please feel free to contact us.
1. Lai Y, et al. Current status and perspectives of patient-derived xenograft models in cancer research. Journal of hematology & oncology, 2017, 10(1): 106.
2. Siolas D, Hannon G J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer research, 2013, 73(17): 5315-5319.